Nodakenin alleviates ovariectomy-induced osteoporosis by modulating osteoblastogenesis and osteoclastogenesis

文献类型： 外文期刊

第一作者： Liu, Chunxiao

作者： Liu, Chunxiao;Chen, Jingyue;Xu, Liwen;Wang, Kaiying;Liu, Chunxiao;Zhao, Mengdi;Li, Guangyu;Zhao, Mengdi;Li, Guangyu

作者机构：

关键词： Nodakenin; Osteoporosis; Osteoclastogenesis; Osteoblast formation

期刊名称：EUROPEAN JOURNAL OF PHARMACOLOGY （ 影响因子：5.0； 五年影响因子：4.6 ）

ISSN： 0014-2999

年卷期： 2023 年 960 卷

页码：

收录情况： SCI

摘要： Osteoporosis, a systemic bone disease defined by decreased bone mass and deterioration of bone microarchitecture, is becoming a global concern. Nodakenin (NK) is a furanocoumarin-like compound isolated from the traditional Chinese medicine Radix Angelicae biseratae (RAB). NK has been reported to have various pharmacological activities, but osteoporosis has not been reported to be affected by NK. In this study, we used network pharmacology, molecular docking and molecular dynamics simulation techniques to identify potential targets and pathways of NK in osteoporosis. We found that NK treatment significantly promoted osteogenic differentiation of BMSCs while activating the PI3K/AKT/mTOR signalling pathway by measuring alkaline phosphatase activity and the expression of various osteogenic markers. In contrast, LY294002, an inhibitor of PI3K, reversed these changes and inhibited the osteogenic differentiation-enabling effect of NK. Meanwhile, prevent the Akt and NF kappa B signalling pathways by down-regulating c-Src and TRAF6 thereby effectively inhibiting RANKL-induced osteoclastogenesis. In addition, oral administration of NK to mice significantly elevated bone mass and ameliorated ovariectomized (OVX)-mediated bone microarchitectural disorders. In conclusion, these data suggest that NK attenuates OVX-induced bone loss by enhancing osteogenesis and inhibiting osteoclastogenesis.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序